P&G Recalling 3 Lots Of Vicks Sinex Nasal Spray
Posted on Thursday, 19 of November , 2009 at 9:19 pm
CINCINNATI, OHIO—The Procter & Gamble Company is voluntarily recalling three lots of its Vicks Sinex nasal spray in three countries: the United States, Germany and the United Kingdom.
The company said it is taking this precautionary step after finding the bacteria B. cepacia in a small amount of product made at its plant in Gross Gerau, Germany. There have been no reports of illness. However, the bacteria could cause serious infections for individuals with a compromised immune system, or those with chronic lung conditions, such as cystic fibrosis. B. cepacia poses little risk to healthy individuals.
P&G detected this problem during routine quality control at the plant and promptly took action. The company’s analysis to date shows this problem is limited to a single batch of raw material mixture involving three lots of product. These three lots were sold only in the United States, Germany and the United Kingdom
P&G is removing the product in question from store shelves and has informed regulatory authorities in the affected countries. P&G said it found the bacteria in a small amount of product from U.S. lot 9239028831 and is conducting testing on the U.K. and German lots that have been produced from the same batch of raw material mixture.
The lot numbers of the products involved are:
|
Lot # |
Country |
Product Name |
| 9239028831 | United States | Vicks Sinex Vapospray 12-Hour Decongestant Ultra Fine Mist, 15 ml., Nasal Spray |
| 9224028832 | United Kingdom | Vicks Sinex Micromist Aqueous Nasal Spray Solution, 15 ml |
| 9224028833 | Germany | Wick Sinex Schnupfenspray Dosiersystem, 15 ml |
This lot number is listed on both the outer carton and the bottle. Consumers should simply discard the affected product as they would any OTC medicine.
Anyone who has these specific lots of this product can call P&G for a replacement coupon or refund at the following numbers:
From the United States, please call: 1.877.876.7881 (Hours of operation: Monday – Friday, 9AM – 6PM US ET, Saturday – Sunday, 9AM – 4PM US ET)
Any adverse events with the use of this product and/or quality problems should be reported via the FDA’s MedWatch Program by fax at 1-800-FDA-0178, by mail at MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch Web site at www.fda.gov/medwatch. 11-19-09
Subscription Needed. First time visitors to The North Country Gazette are welcome at no charge. Thereafter, readers who wish to read additional articles or plan on returning at a later time will need to be an advertiser or have a paid subscription to the NCG Daily Digest in order to gain access. This policy will be strictly enforced and access will be denied to those who abuse it. To sign up, see the subscription ad and PayPal button to the right of this page or at www.northcountrygazette.org If you have questions, contact us at news@northcountrygazette.org
Category: Business, Government, Health, Nationwide
- Add this post to
- Del.icio.us -
- Meneame -
- Digg
COPYRIGHT 2009 - NORTH COUNTRY GAZETTE All rights reserved. This material may not be published, broadcast, rewritten or redistributed without the express written permission of the publisher.
